NEW YORK, Feb. 24, 2025 /PRNewswire/ -- An affiliate of the fund known as EQT VIII ("EQT") is pleased to announce the completion of an underwritten public offering (the "Offering") of 23 million shares of common stock of Waystar Holding Corp. (NASDAQ: WAY) (the "Company") ("Shares") for aggregate gross proceeds of USD920 million. As part of the Offering, EQT sold c. 9.8 million Shares (and now holds c. 38.8 million Shares) and received gross proceeds of c. USD393 million. The remaining Shares sold in the Offering were sold by other stockholders of the Company. J.P. Morgan, Goldman Sachs & Co. LLC and Barclays acted as joint book-running managers of the Offering, which was completed on February 24, 2025, and as representatives of the several underwriters. The Company did not sell any Shares in the Offering and did not receive any proceeds from the sale of the Shares sold by EQT and the other stockholders.
Contact
EQT Press Office, This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$40.36 |
| Daily Change: | 0.90 2.28 |
| Daily Volume: | 735,179 |
| Market Cap: | US$6.950B |
April 30, 2025 April 30, 2025 April 23, 2025 February 18, 2025 February 18, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
